Sandoz Group Business Model Canvas

Active engagement with EMA, FDA and WHO accelerates approvals and regulatory clarity; by 2024 regulators had approved over 50 biosimilars in the US and 80+ in Europe, underpinning market access. Scientific advice from agencies de‑risks study designs and comparability exercises, lowering late‑stage failure risk. Close compliance collaboration improves inspection outcomes and audit readiness. Participation in policy forums drives biosimilar adoption and reimbursement reform.

Sandoz leverages long‑term API/CMO contracts, multi‑sourcing and tech transfers to secure supply, control cost and accelerate scale‑up. Biotech alliances and co‑development spread R&D risk and speed biosimilar filing; regulators and scientific advice de‑risk approvals. Tier‑1 wholesalers, logistics and payer/hospital tenders enable reach across 100+ countries and multi‑year volumes.

Global dossier preparation, submissions and variations drive Sandoz market entry across >100 markets, with coordinated filings to meet EMA and FDA timelines; in 2024 EU FMD and US DSCSA serialization and traceability requirements remained enforced. Patent landscaping and targeted Paragraph IV/UPC strategies time launches to patent expiries and litigation windows. Pharmacovigilance operations monitor safety and regulatory compliance across the portfolio.

R&D delivers regulatory-ready formulations, PK/PD biosimilarity packages and lifecycle cost optimization. GMP manufacturing for small molecules, injectables and biologics (cold-chain 2–8°C) supports supply to >100 markets. Global filings, pharmacovigilance, tendering, HTA engagement and S&OP align launches and tender-driven supply in 2024.

Comprehensive CTDs, analytical libraries and stability data enable accelerated filings and robust comparability packages that protect launches in markets where generics account for ~90% of prescriptions as of 2024. Process, formulation and comparability know-how form a technical moat reducing risk and cost of scale-up. Freedom-to-operate analyses time launches; real-world evidence programs drive faster uptake and payer acceptance.

Sandoz key resources: ~25,000 employees, >20 global manufacturing sites, operations in >100 countries (2024); deep regulatory/CTD libraries and QA/QC teams enabling accelerated filings; approved vendor network and payer/wholesale relationships securing supply and tenders; biosimilar expertise delivering 30–50% cost reductions and ~20% adherence uplift.

Broad therapeutic coverage across CV, CNS, pain, oncology, respiratory and anti-infectives simplifies sourcing and supports customers in over 100 countries; generics represent about 90% of prescriptions in the US, underscoring demand. One-stop contracting reduces administrative burden and procurement cycles. Standardized packs and SKUs streamline operations and inventory. Regular portfolio refreshes sustain market relevance and price competitiveness.

Competitive pricing and biosimilars drive cost savings and access, supporting continuity of care via scaled multi-site manufacturing and high fill rates. Rigorous GMP, >100 annual audits and robust comparability data secure market access and clinician confidence. HEOR, switching support and access programs extend reach to underserved populations.

Multi-year tenders (commonly 2–5 years) and rebate frameworks secure stable procurement ties and predictable volumes; Sandoz operates in over 100 countries, leveraging scale. SLAs define fill rates (typical targets >95%), lead times and quality standards. Transparent pricing models foster long-term cooperation, while regular performance reporting sustains credibility with payers and distributors.

Account teams serve wholesalers, GPOs and hospitals in 100+ countries, using monthly KPI reviews and exec sponsorship to maintain >95% fill rates. Medical affairs supports clinicians (40+ FDA biosimilars by 2024) and 100+ RWE studies (2024). Digital portals, EDI (~50% fewer errors) and analytics (+20–30% forecast accuracy) cut stockouts ~20%.

Placement in retail pharmacies drives patient access for chronic therapies, with 90% of patients living within close proximity to a community pharmacy (NACDS 2024), enabling adherence initiatives and scale. Specialty channels manage complex biologics and cold-chain logistics, reflecting specialty medicines accounting for about 48% of global medicine spend in 2024 (IQVIA). Co-pay support programs integrate where permitted to lower out-of-pocket costs, while targeted pharmacy education programs facilitate safe switches and adherence.

Wholesalers/distributors reach 100+ countries, central hubs cut cost-to-serve and enable pooled inventory. Direct hospital contracts secure predictable volumes for generics/biosimilars; on-time-in-full and fill rate tracked. Retail pharmacies (90% patient proximity, NACDS 2024) and specialty channels (48% global spend 2024) handle adherence and cold-chain. Public procurement (~60% in low-income markets, 2024) and WHO prequalification expand tenders.

Retail and specialty pharmacies dispense the bulk of chronic therapies and biologics, with specialty drugs accounting for roughly 55% of US drug spend in 2024. They require predictable inventory and integrated patient-support programs to manage adherence and provider coordination. Tight margin structures driven by payer contracts force competitive pricing and rebate management. Clear, regulator-compliant education materials are essential to effective patient counseling.

Hospitals & health systems prioritize reliable supply, quality and tender-driven value; wholesalers/GPOs drive ≈80% of US hospital purchasing (2024).

Retail/specialty pharmacies manage chronic/biologic dispensing; specialty drugs ≈55% of US drug spend (2024).

Payers favor biosimilars (30–60% price reduction), contributing ≈$250B system savings 2014–2024; RWE and safety surveillance required.

Clinician/patient trust and adherence (~50% chronic) hinge on continuity and access programs.

Inspections, audits and QMS operations are recurring cost drivers, with Sandoz sites facing hundreds of regulatory and GMP inspections annually across markets. Serialization, track-and-trace and pharmacovigilance programs add ongoing overhead and technology spend; industry estimates put PV and serialization budgets in the low-single-digit percent range of pharma operating costs. Documentation, dossier submissions and translations consume significant headcount and consultancy resources. Remediation reserves are maintained to mitigate inspection-related risk and potential recall costs.

APIs/excipients, utilities and labor drive ~60–80% of COGS for Sandoz generics; biologics incur ~2–3x higher sterile/cold-chain capex and OPEX. OEE/yield (typically 60–75%) meaningfully shifts unit COGS (each 1% yield ≈1–2% COGS change); validation/maintenance add ~5–10% annually. PV/serialization and compliance consume low-single-digit percent of operating costs; inspections number in the hundreds annually.

Sales of active ingredients and contract manufacturing provide diversification by adding API and third-party supply revenues alongside finished-dose generics. Long-term supply agreements deliver multi-year revenue visibility and reduce demand volatility. Higher capacity utilization in manufacturing drives margin expansion, while Sandozs quality reputation and regulatory track record attract multinational clients and contract wins.

Generics drive high-volume, low-margin sales (~90% of US Rx by volume, FDA 2024) with lifecycle management preserving share. Biosimilars are higher-value (global market ~USD 30B in 2024) and rely on access programs and tenders for recurring revenue. API/CMO and multi-year contracts diversify cash flows; emerging markets growth ~6% (IQVIA 2024) and public procurement ~40% generics (WHO 2024) shape pricing.